|
About the Nitrosamines in the News category
|
|
0
|
437
|
April 14, 2021
|
|
Controversial but Public Report
|
|
0
|
756
|
November 6, 2023
|
|
FDA Updates Recall on Blood Pressure Medication Due to Possible Carcinogen
|
|
3
|
711
|
December 27, 2024
|
|
Phathom Pharmaceuticals reported nitrosamine impurity in their vonoprazan-based products
|
|
24
|
2924
|
November 26, 2024
|
|
Varenicline back available in the UK
|
|
0
|
128
|
November 12, 2024
|
|
Cinacalcet Recall
|
|
3
|
730
|
November 4, 2024
|
|
4000 Members Milestone 🎉
|
|
21
|
921
|
October 24, 2024
|
|
Nationwide recall of duloxetine
|
|
0
|
233
|
October 23, 2024
|
|
"Ribolaris" clinical trial has been partially suspended due to nitrosamine impurities in ribociclib batches
|
|
1
|
170
|
October 16, 2024
|
|
Presencia de Nitrosaminas en Materiales de empaque. Presence of Nitrosamines in packaging materials
|
|
4
|
328
|
September 23, 2024
|
|
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark
|
|
0
|
86
|
September 18, 2024
|
|
Novartis pauses some trials of cancer drug Kisqali to fix manufacturing
|
|
13
|
1859
|
September 9, 2024
|
|
Pfizer Japan Seeks Partial Change of Champix’s Approval towards Re-Supply
|
|
0
|
144
|
September 2, 2024
|
|
Health Canada: Nitrosamine impurities Update July 26, 2024
|
|
14
|
1124
|
August 26, 2024
|
|
Suppressing Nitrosamine Drug Substance Related Impurities by Solid Dispersion
|
|
1
|
271
|
August 22, 2024
|
|
Pharmaceutical industry wants FDA to extend deadline for testing novel nitrosamines
|
|
3
|
1168
|
July 21, 2023
|
|
Withdrawal of application for the marketing authorisation of Dabigatran etexilate
|
|
1
|
330
|
June 30, 2024
|
|
Namibia Medicines Regulatory council (NMRC) has withdrawn all ranitidine products from the Namibian market
|
|
0
|
221
|
May 23, 2024
|
|
In light of recently evolving regulatory guidance on intake limits for nitrosamines in medications, enrollment of new patients in ribociclib early breast cancer (eBC) studies has been paused by Novartis in alignment with health authorities
|
|
0
|
261
|
May 21, 2024
|
|
Namibia Medicines Regulatory Council (NMRC) issues order for Withdrawal of all Ranitidine containing products from Namibian market due to NDMA impurities
|
|
0
|
271
|
May 20, 2024
|
|
Ranitidine back in the news!
|
|
2
|
385
|
May 15, 2024
|
|
Korean drug manufacturers are taking voluntary action by recalling or suspending the sales of tamsulosin, citing potential NDSRI impurity, N-Nitroso-tamsulosin concern
|
|
12
|
1128
|
April 18, 2024
|
|
Nitrosamine Impurity Test Market expected to grow exponentially by 2029
|
|
0
|
583
|
November 19, 2023
|
|
Nitrosamines in Bacon: a Case Study of Balancing Risks
|
|
1
|
291
|
March 20, 2024
|
|
NEWS! New USP Community on qNMR
|
|
0
|
360
|
March 1, 2024
|
|
Quality Officer Call for a New approach to Reduce Post Approval Complexity
|
|
0
|
293
|
February 28, 2024
|
|
📰 Nitrosamine measures might disrupt anesthetic supply, Dr. Eric Tichy says
|
|
4
|
521
|
January 26, 2024
|
|
FDA leaders detail reorg plans Webinar
|
|
0
|
288
|
January 23, 2024
|
|
🇪🇺 Ph. Eur. Commission adopts revised general monographs 2034 and 2619 after inclusion of new paragraph on control of N-nitrosamines
|
|
1
|
904
|
January 22, 2024
|
|
US FDA- Generic Drug Science and Research Priority Initiatives for Fiscal Year (FY) 2024
|
|
0
|
435
|
January 18, 2024
|